Shire filed a new-drug application with the FDA for velaglucerase alfa, a treatment for patients with Type 1 Gaucher disease, ahead of schedule. The company expedited development of the drug amid a shortage of rival drug Cerezyme, caused by a viral contamination at Genzyme's manufacturing facility in Boston.

Related Summaries